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1
22 ABSTRACT  
23 Novel therapeutics designed to target the polymeric matrix of biofilms, require novel 
24 techniques to accurately assess their efficacy. Here, multiple particle tracking (MPT) 
25 was developed to characterize the physical and mechanical properties of antimicrobial 
26 resistant (AMR) bacterial biofilms and to quantify the effects of antibiotic treatment.
27 Studies employed nanoparticles (NPs) of varying charge and size (40-500 nm) in 
28 Pseudomonas aeruginosa PAO1 and methicillin resistant Staphylococcus aureus
29 (MRSA) biofilms and also in polymyxin B (PMB) treated Escherichia coli biofilms of 
30 PMB-sensitive (PMBSens) IR57 and PMB-resistant (PMBR) PN47 strains. NP size-
31 dependent and strain-related differences in the diffusion coefficient values of biofilms 
32 were evident between PAO1 and MRSA. Dose-dependent treatment effects induced by 
33 PMB in PMBSens E. coli biofilms included increases in diffusion and creep compliance (P
34 < 0.05), not evident in PMB treatment of PMBR E. coli biofilms.  Our results highlight 
35 the ability of MPT to quantify the diffusion and mechanical effects of antibiotic therapies 
36 within the AMR biofilm matrix; offering a valuable tool for the pre-clinical screening of 










46 The important role of bacterial biofilms in chronic human disease, such as cystic fibrosis, 
47 otitis media, chronic skin wounds and implant- and catheter-associated infections, has 
48 been increasingly recognized1.  Within these biofilms, the bacteria are embedded in a 
49 complex, charged, self-produced extracellular polymeric matrix (EPS).  The EPS matrix 
50 is an entangled polymer network2 predominately composed of polysaccharides, 
51 extracellular DNA (eDNA), proteins and lipids, which facilitates biofilm formation and 
52 maturation3.  The matrix confers considerable fitness advantages over planktonic bacteria 
53 in hydration, protection from environmental tensile or shear forces, increased cell-cell 
54 communication and enhanced horizontal gene transfer4.  The EPS matrix also offers 
55 protection from antimicrobials, as bacteria within biofilm structures can resist 
56 conventional antibiotic therapies up to 103-fold5-7.  This inherent ability of biofilms to 
57 resist antibiotics occurs through reduced metabolic activity, development of persister 
58 cells8 and reduced antibiotic/ small molecular diffusion through the EPS polymeric 
59 network via charge-interactions9-11.
60 The global rise of antibiotic resistance is an increasing problem, threatening the 
61 ability of healthcare providers to treat common bacterial infections, such as hospital-
62 acquired methicillin-resistant Staphylococcus aureus (MRSA)12.  Multidrug resistance in 
63 bacteria is also of increasing concern due to their ability to acquire multiple resistance 
64 mechanisms through horizontal gene transfer.  More worrying still is the emergence of 
65 resistance to the so called ‘antibiotics of last resort;’ i.e. the polypeptide polymyxin 
66 antibiotics13, 14, particularly those carried on mobile genetic elements such as plasmids.  
67 The colistin resistant mcr-1 gene is most often isolated in E. coli15, 16, although recently it 
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68 has also been found to have spread to Klebsiella sp. carried on a broad host range, self-
69 transferable IncP plasmid17 suggesting the high likelihood of imminent further spread to 
70 other Gram-negative species. 
71 Modification of biofilm assembly and targeted disruption of the cross-linked 
72 network of “entangled polymers” within the biofilm EPS matrix would be advantageous 
73 in both clinical and industrial applications, especially with the global rise of antibiotic 
74 resistance.  Most strategies fall into one of two categories; biofilm disruption or biofilm 
75 prevention.  To date, anti-biofilm strategies have amongst others, included 
76 surface/substrate modification (to modify initial bacterial adhesion)18; disruption of the 
77 biofilm matrix using conventional antibiotics19; antimicrobial peptides20; dispersal 
78 agents21; detergents22; chelators (e.g. EDTA)23; EPS synthesis inhibitors24 and 
79 dysregulation of quorum sensing within biofilms25, 26.  In attempting to design and deliver 
80 new antimicrobial and anti-biofilm therapies, the ability to accurately measure the effects 
81 of such potential therapies upon the biofilm and biofilm matrix, and accurately quantify 
82 the complexity and variability of these biofilms is currently challenging.  Conventional 
83 biofilm characterization techniques include scanning electron microscopy (SEM) and 
84 confocal laser scanning microscopy (CLSM), often combined with image analysis.  
85 These techniques however, fail to accurately characterize the EPS structure of treated 
86 biofilms, due to extensive sample preparation and/or sample dehydration, or the lack of 
87 universal dyes for EPS staining27.  Moreover, the EPS biofilm matrix varies depending on 
88 species, strain and growth environment, for example P. aeruginosa produces different 
89 types of polysaccharides with varying charge namely, cationic Pel and neutral Psl, as well 
90 as anionic alginate28-30 which further complicates characterization.  
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91 To understand the key ‘fitness’ advantages that biofilms possess against 
92 antimicrobial treatment, workers have sought to characterize the diffusion and material 
93 properties of the whole biofilm matrix using mesoscale and nanoscale technologies, 
94 without the need to visualize the actual EPS matrix itself.  Such technologies include 
95 shear and extensional rheology31, 32, fluorescence correlation spectroscopy (FCS)33, 34 and 
96 fluorescence recovery after photobleaching (FRAP)35.  Both FCS and FRAP employ 
97 fluorescently-labeled particles which can be traced within the biofilm structures.  In 
98 FRAP, an area of biofilm is photo-bleached and fluorescence recovery (into the area) is 
99 modelled to determine diffusion parameters, whereas FCS is based on diffusion 
100 measurements from single-molecule fluorescence intensity fluctuations within a discrete 
101 region within the biofilm34, 36. 
102 Multiple particle tracking (MPT) is a recently described technique, allowing 
103 simultaneous tracking of nano-sized particles using fluorescent microscopy, from which 
104 the diffusion-based parameters of embedded particles within the EPS of bacterial 
105 biofilms can be determined37.  MPT also facilitates measurement of the micro-rheological 
106 properties of biofilms38.  MPT, when used in conjunction with nanoparticles (NPs) of 
107 discrete size and charge, represents a non-invasive technique which can be readily 
108 employed in situ within biofilms.  MPT has subsequently been employed to characterize 
109 the diffusion properties of NPs within biofilms of a range of bacterial species including 
110 P. aeruginosa, E. coli, P. fluorescens and S. aureus and also to determine time-dependent 
111 changes in the biofilm matrix following adhesion36, 37, 39, 40.  
112 In this study, we sought to develop the MPT biofilm model to detect variations in 
113 the biofilm structure of Gram-negative P. aeruginosa and Gram-positive S. aureus
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114 biofilms and examine its sensitivity and correlation to CLSM imaging.  Using polymyxin 
115 B sensitive (PMBSens) and resistant (PMBR) E. coli strains, we examined the sensitivity of 
116 the MPT biofilm model to detect variations in the biofilm structure after dose-dependent 
117 polymyxin B antibiotic therapy in comparison to traditional confocal microscopy.  By 
118 using commercially available NPs, this study highlights the usefulness and sensitivity of 




123 CLSM imaging and MPT measurements identify distinct variations in S. aureus
124 and P. aeruginosa biofilms.  CLSM imaging of S. aureus 1004A (MRSA) and P. 
125 aeruginosa PAO1 revealed variation in the structural properties of the biofilms produced 
126 by the two strains.  While MRSA formed a thin, but bacterially-dense biofilm structure, 
127 PAO1 biofilms possessed greater height, but appeared less bacterially-dense 
128 (Supplementary Fig. 1).  These CLSM images correlated well with diffusion of the 
129 negatively-charged NPs (40–500 nm) through the biofilm, with NP diffusion being lower 
130 in the MRSA biofilms when compared to those of PAO1 (40 and 200 nm NPs; P < 0.01).  
131 In contrast, diffusion of the positively-charged NPs (200 nm) in both biofilms were 
132 similar (P > 0.05; Table 1).  
133 MPT revealed that as the size of the negatively-charged particles increased, the 
134 diffusion coefficient of the particles within PAO1 biofilms decreased significantly (40-
135 200 nm; P < 0.05).  This significant trend was also evident in the MRSA biofilms for 
136 particle sizes of 40-200 nm.  Also, while diffusion of the positively charged 200 nm NPs 
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137 in PAO1 biofilms was significantly reduced when compared with the diffusion of the 
138 negatively-charged NPs of the same size (P < 0.05), in MRSA biofilms, the diffusion of 
139 the positively-charged NPs was not significantly different when compared to the 
140 negatively-charged particles (P > 0.05; Table 1).
141 The ratio of the biofilm diffusion coefficient to the diffusion coefficient in water 
142 (<Deff>/Do) allows measurement of NP diffusion through the biofilm structure in relation 
143 to the intrinsic free Brownian motion of the NPs in water, thereby taking into account the 
144 impact of NP size on its unrestricted diffusion in liquid.  The percentage ratio of 
145 <Deff>/Do revealed that the diffusion of 200 and 500 nm sized NPs were significantly 
146 lower than diffusion of 40 and 100 nm NPs in both MRSA and PAO1 biofilms (P < 
147 0.05).  However, negatively-charged NP diffusion was still greater (by at least 2.5 times) 
148 in PAO1 biofilms when compared to their diffusion in MRSA biofilms (Table 1).  
149 PAO1 biofilms displayed greater heterogeneity in negatively-charged NP movement 
150 with resultant 90th/10th percentile ratios of 100-987, when compared to MRSA biofilms 
151 which displayed much lower ratios of 3-85 (Fig. 1).  The heterogeneity data again 
152 confirmed the observed variations in the structural properties between the MRSA and 
153 PAO1 biofilms seen in the CLSM images.  The data also revealed that there was 
154 increasing heterogeneity in NP diffusion with increasing particle size until the NP size 
155 reached 100 nm for S. aureus and 200 nm for P. aeruginosa biofilm systems, after which 
156 heterogeneity in NP diffusion then decreased.
157 The exponential anomalous values of both PAO1 and MRSA biofilms calculated 
158 using 40-500 nm NPs appeared to demonstrate a viscous response of these biofilms (α > 
159 0.5; Fig 2).
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160 CLSM and MPT measurements describe dose-dependent disruption of E. coli
161 IR47 biofilms treated with polymyxin B.  MIC assays of PMBSens E. coli IR57 and
162 PMBR E. coli PN47 were performed to confirm strain sensitivity to the antibiotic, giving 
163 MIC values against polymyxin B of 0.06 and 2 µg/ml respectively.  
164 The CLSM assay revealed cellular aggregation and disruption of the PMBSens E. coli
165 IR57 biofilm matrix in a dose-dependent manner following polymyxin B treatment (Fig 
166 3a).  This finding was confirmed by MPT through dose-dependent increases in the 
167 effective diffusion coefficients (<Deff>) within the treated biofilms for all three NP sizes 
168 tested (100, 200 and 500 nm; Fig. 3), with the 100 nm NPs revealing the greatest dose-
169 dependent sensitivity in diffusion coefficients to antibiotic treatment.  The dose-
170 dependent changes in NP diffusion coefficients, starting from 2 µg/ml polymyxin B 
171 treatment, were all significantly different from the control (P < 0.05).
172 Polymyxin B treatment (2-8 µg/ml) revealed a greater increase in the mean square 
173 displacement <MSD> versus time measurements for the 200 and 500 nm particles when 
174 compared to the 100 nm particles, indicative of increasing pore size within the biofilm 
175 structure following polymyxin B treatment (Fig. 4). The exponential anomalous values of 
176 the E. coli biofilms demonstrated that polymyxin B treatment had little effect on the 
177 viscoelastic response of the biofilms (Fig. 4). However, the dose–dependent disruption of 
178 the E. coli IR57 biofilms was reflected in increasing biofilm creep compliance (J(Ƭ)) with 
179 increasing polymyxin B dose, observed with all 3 NP sizes tested (Fig. 5). 
180 MPT measurements describe distinct variations in the response of PMBSens E. 
181 coli IR47 and PMBR E. coli PN47 biofilms to polymyxin B treatment.  To assess the 
182 impact of resistance to polymyxin B on treatment of E. coli biofilms, two strains of E. 
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183 coli (PMBR PN47 and PMBSens IR45) were selected based on their susceptibility to 
184 polymyxin B.  The MPT assay revealed that the diffusion coefficients <Deff> of 200 nm 
185 NPs was greatly increased in the PMBSens IR45 biofilms (0.0643 vs. 0.34 cm2. s-1 x 10-9) 
186 following treatment, while NP diffusion within the PMBR PN47 biofilms remained 
187 largely unchanged (Table 2).  This trend was reflected in the heterogeneity of the NP 
188 diffusion measurements (Fig. 6), where the PMBSens IR45 demonstrated decreased 
189 90th/10th percentile ratio of 2577 to 198 following treatment, revealing more homogenous 
190 NP diffusion, indicative of increasing biofilm pore size with antibiotic treatment.  As 
191 before, the heterogeneity of the NP diffusion measurements within the PMBR PN47 
192 biofilms demonstrated little response to treatment.  This result was also confirmed by the 
193 creep compliance data showing increasing values following polymyxin-B treatment in the 
194 PMBSens strain, but not in the PMBR strain (Fig. 7).  Interestingly, NP diffusion (<Deff>) 
195 for the PMBSensIR45 was more than 3 times greater than <Deff> for PMBR PN47 (Table 
196 2).  NP diffusion within the PMBSens strain appeared to be vastly more heterogeneous 
197 than for the PMBR strain, indicating that pore size was more heterogeneous in the 
198 biofilms of the PMBSensstrain (Fig. 6).
199
200 DISCUSSION
201 NPs are being increasingly applied in a variety of medical applications, such as in the 
202 diagnosis and treatment of human disease (e.g. drug- and gene delivery)41 and as novel 
203 research tools (both in vitro and in vivo) to improve our understanding of biological 
204 systems and human illness42-44. This study has demonstrated the use of MPT with 
205 traceable NPs as a robust, non-invasive, in situ technique to inform our understanding of 
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206 biofilms and further our insight into the potential effects of antimicrobial and anti-biofilm 
207 therapies on the biofilm matrix, and on biofilm-related changes induced with the 
208 acquisition of antibiotic resistance. 
209 The EPS matrix of biofilms varies not only between species and strains, but also with 
210 differences in environmental growth conditions, such as surface composition/roughness, 
211 nutrient availability, temperature, and hydrodynamic shear38, 45.  As a result, the net 
212 charge and functional groups present within the matrix, as well as biofilm pore size 
213 exhibit considerable variations.  To assess variations in biofilm structure between 
214 bacterial species, the diffusion coefficients of fluorescently-labelled NPs were initially 
215 measured in both Gram-positive S. aureus 1004A (MRSA) and Gram-negative P. 
216 aeruginosa PAO1, revealing the influence of both NP size and surface-charge on 
217 diffusion through the respective biofilm structures.  The influence of NP charge was 
218 clearly evident in the diffusion coefficient measurements of 200 nm NPs within P. 
219 aeruginosa PAO1 biofilms, with reduced diffusion of amine-modified (positively-
220 charged) particles compared to the carboxylated (negatively-charged) NPs.  In P. 
221 aeruginosa PAO1, the exopolysaccharides form a major part of the EPS matrix and are 
222 composed of negatively-charged alginate, neutrally-charged Psl and positively-charged 
223 Pel, while eDNA in biofilm matrixes has been shown to be negatively-charged46. Our 
224 results indicate a net negative charge of the P. aeruginosa EPS matrix, where the 
225 existence of increased negative charges within the EPS matrix reduced the diffusion 
226 coefficient of the positively-charged amine-modified NPs.  In S. aureus MRSA biofilms, 
227 whilst the diffusion coefficient of the amine-modified NPs was 2X that of the 
228 carboxylated-modified NPs, these values were not significant different.  In S. aureus, the 
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229 two major components of EPS matrix are the positively-charged poly-N-
230 acetylgluosamine (PNAG) polysaccharides and negatively-charged eDNA47, 48. These 
231 results potentially indicate a net positive charge of the MRSA EPS matrix; increased 
232 positive charges within the matrix reducing the diffusion coefficient of the negatively-
233 charged carboxylated NPs. However, as the diffusion coefficient values achieved with 
234 200 nm carboxylated NPs were similar to those observed with 500 nm NPs in MRSA 
235 (0.0031 vs 0.0038 cm2 S-1 x10-9 respectively), this indicates the inability of the 200 nm 
236 NPs to freely move within the dense MRSA biofilm matrix.  The restricted movement of 
237 200 nm NPs within the MRSA biofilms resulted in small, distinct differences in diffusion 
238 coefficient between the amine-modified NPs and carboxylated-modified NPs, which may 
239 have been more pronounced with the use of smaller sized amine-modified NPs.
240 In this model, NP diffusion into the biofilm EPS matrix was not only clearly 
241 influenced by charge, but also by their size49-51.  Large particles may not be able to 
242 permeate into the biofilm EPS structure due to steric hindrance or biofilm pore size, 
243 while hydrophobic/electrostatic interactions may influence the diffusion of smaller 
244 particles38.  Previous researchers have used a variety of techniques to characterise the 
245 internal structure and pore size of biofilms.  Zhang et al52 originally employed sectioning 
246 by microtome and dye adsorption to describe the heterogeneity in pore size within 
247 wastewater biofilms, where biofilm pore sizes ranged from 0.3-2.7 µm.  More recently, 
248 Rosenthal et al (2018)53 used optical coherence tomography (OCT) to characterize the 
249 heterogeneous network of a thick, multi-species biofilm, where pore diameters as large as 
250 110 µm were measured, while other researchers have demonstrated pore size ranges of 
251 500-1000 nm54 and >100 nm55 using single-particle tracking techniques. 
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252 In the current study, the effect of NP size on diffusion was clearly evident in PAO1 
253 and MRSA biofilms, where a reduction in NP size (< 200 nm), induced a dramatic rise in 
254 particle diffusion; a finding possibly indicative of a mean biofilm pore size < 200 nm.  
255 Similarly, Peulen and Wilkinson56 demonstrated increasing diffusion coefficients with 
256 decreasing size and negative charge of silver NPs in Pseudomonas fluorescens biofilms, 
257 where the optimum particle size for diffusion in these dense biofilms was < 50 nm.  The 
258 increased NP diffusion coefficients in PAO1 biofilms when compared to the MRSA 
259 biofilms (40-500 nm carboxylated-modified NPs) was evident in this study and reflected 
260 the biofilm architecture; CLSM imaging demonstrating the more dense structure of the 
261 MRSA biofilms.  
262 Profiling of the diffusion coefficients of 360 individual particles through ranking 
263 <Deff> data into percentiles (highest 90th to lowest 10th percentiles) provides insight 
264 into the heterogeneity of particle movement, which may be indicative of heterogeneous 
265 pore sizes within the biofilm itself57, 58.  This study revealed that NP diffusion coefficients 
266 became more heterogeneous with increasing particle size until a NP size of 100 nm for S. 
267 aureus and 200 nm for P. aeruginosa biofilms was reached, at which point NP diffusion 
268 became more homogeneous (the particle size becoming too large to facilitate free 
269 movement within the biofilm structure) with NP movement occurring only through larger 
270 pore sizes.  This data demonstrates contrasting inter-species biofilm architecture; P. 
271 aeruginosa forming a pore structure that was larger in size and more heterogeneous 
272 compared to that of S. aureus biofilms.  
273 MPT may, in the future, offer valuable insight in characterizing the EPS matrix of 
274 heterogeneous polymicrobial biofilms which are commonly found in human disease 
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275 states59, 60. Whilst these biofilms are heterogeneous, they are often composed of distinct, 
276 individual ‘pockets’ of homogenous single-species growth and MPT coupled with GFP-
277 labelled bacterial populations or Fluorescence in situ hybridization (FISH) labelling may 
278 be employed to visualize and analyse the biofilm matrix of these bacterial populations. 
279 Structurally, biofilms possess a complex architecture, being composed of cell 
280 clusters surrounded by voids and water channels61. Biofilm structures possess viscoelastic 
281 properties (exhibiting both elastic and viscous properties) which can aid biofilm survival 
282 under mechanical and chemical loads62, 63.  Cao et al37 employed single particle tracking 
283 with CLSM imaging to characterize the viscoelastic properties of cell clusters and voids 
284 within P. fluorescens biofilms, demonstrating that the viscoelastic properties (creep 
285 compliance) of the ‘biofilm void’ zones was the primary contributor to the viscoelastic 
286 properties of the biofilm.  Importantly, whilst the larger (500 nm) NPs employed in this 
287 study were unable to diffuse into the bacterial cell clusters, their diffusion into the biofilm 
288 voids could still provide a sensitive and reproducible model to monitor changes in the 
289 viscoelastic properties of biofilms.  In this study, calculation of the exponential 
290 anomalous values revealed that PAO1 and MRSA biofilms displayed viscous behavior 
291 when assessed using 40 – 500 nm NPs however, no micro-rheological differences could 
292 be determined between the well-established 72 h grown PAO1 and MRSA biofilms.
293 The resistance of bacterial biofilms to antibiotic therapy has been widely reported in 
294 the literature, with high levels of antibiotic tolerance arising due to a number of different 
295 factors64.  Penetration of antibiotics through the biofilm EPS matrix can vary 
296 considerably depending on how they interact with the charged components of the EPS10, 
297 11.  Previous research has shown that cationic antibiotics (e.g. tobramycin) exhibit charge-
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298 mediated binding to polyanions within the biofilm EPS matrix, resulting in reduced 
299 penetration of antibiotics into the biofilm structure9, 65. Sankaran et al34, however, 
300 demonstrated that both labelled aminoglycoside tobramycin (positively-charged) and the 
301 fluoroquinolone ciprofloxacin (neutrally-charged) were able to diffuse into, and remained 
302 mobile within the interior of P. aeruginosa biofilms, demonstrating that reduced 
303 antibiotic diffusion in the EPS matrix is not solely responsible for the antibiotic tolerance 
304 of biofilms66.  Moreover, the development of a sub-population of persister cells (with low 
305 or dormant metabolic activity) may ensure that a small cohort of cells within the biofilm 
306 can withstand multiple doses of antimicrobial therapy67.  Expression of biofilm-specific 
307 genetic mechanisms may also occur11, making the biofilm less susceptible to 
308 antimicrobial attack.
309 Zrelli et al68 and Reighard et al39 demonstrated the failure of antibiotic treatment 
310 (afloxacin, ticarcillin, tobramycin) to induce changes in the NP diffusion and mechanical 
311 properties of E. coli and P. aeruginosa biofilms using particle tracking methodologies.  In 
312 contrast, here we demonstrate the dose-dependent disruption of the PMBsens E. coli
313 biofilm matrix induced by exposure to polymyxin B, with significant increases in NP 
314 diffusion and creep compliance in the treated biofilms.  Klinger-Strobel et al69
315 demonstrated the ability of colistin (polymyxin E) to disrupt 48 h E. coli biofilms at 
316 concentrations of 4-16 mg/ml (with MICs ranging from 1 to 0.0625 mg/ml for laboratory 
317 strains and clinical isolates respectively).  The authors suggested that colistin destabilized 
318 the biofilm matrix (even in strains with intrinsic polymyxin resistance) leading to the 
319 dispersal of planktonic cells that were then more susceptible to antibiotics.  The 
320 published, susceptibility breakpoints for polymyxins are S ≤2 µg/ml > R for E. coli
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321 (EuCAST 2018)70.  The concentrations of polymyxin B used in our study were relatively 
322 high (2 to 64 µg/ml), equal to, or above, the MIC values (0.06 to 2 µg/ml), to induce 
323 effective disruption of the biofilm structure.  However, they were markedly lower than 
324 the concentrations employed by Klinger-Strobel et al69.
325 Witten and Ribbeck38 proposed that biofilm permeability may be a biomarker for 
326 antimicrobial resistance, and the data here demonstrates the sensitivity of the MPT 
327 biofilm assay in this respect.  In the PMBsens E. coli IR57 (MIC 0.06 µg/ml) biofilms, 
328 MPT was able to detect structural, pore-size related changes induced within the biofilm 
329 matrix with antibiotic dosing as low as 2 µg/ml (a clinically-relevant concentration) 
330 where changes in the treated biofilm structure were indiscernible at this concentration 
331 using conventional CLSM imaging.  The disruptive effect of polymyxin B on the E. coli
332 biofilm structure was however, evident in CLSM imaging at higher concentrations (> 32 
333 µg/ml).  We also sought to model biofilm disruption by polymyxin B in PMBR E. coli as 
334 we have previously demonstrated that mcr-1 and -3 expression in E. coli is associated 
335 with alterations in bacterial viability within the biofilm matrix16, 71; hypothesizing that the 
336 acquisition of polymyxin resistant mcr-1 was an evolutionary ‘trade-off’; resistance to 
337 polymyxin being associated with decreased biofilm biomass and growth in 24 h biofilm 
338 formation assays71.  Here we clearly demonstrate resistance to biofilm disruption of 
339 PMBR PN47 following treatment with polymyxin B (8 µg/ml) in well-established 72 h 
340 grown biofilms. 
341 The observed variations in particle diffusion and creep compliance with 
342 antibiotic/antimicrobial treatment in this study could also be crucial in understanding the 
343 interaction of the innate immune system with biofilm infections. Increased pore size and 
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344 decreased mechanical properties of the biofilm structure may facilitate increased 
345 inflammatory cell penetration into the biofilm matrix, thereby improving bacterial 
346 clearance72 Moreover, increased porosity of biofilm structures may allow greater 
347 penetration of antimicrobial agents and may be of benefit, especially in treating implant 
348 biofilm-related infections73. 
349 This study demonstrated not only the ability of MPT to detect disruption in biofilm 
350 structures, but also revealed the ability of the technique to dissect the effects of 
351 antimicrobial and anti-biofilm therapies, not always discernible using conventional 
352 technologies.   Here, the ability of MPT to inform understanding of, and test therapies 
353 against, emergent antimicrobial resistant pathogens is clear.  As anti-biofilm therapies 
354 play a clear role in increasing susceptibility of resistant bacteria to existing therapies, the 
355 utility of MPT in assessing novel therapies to disrupt the biofilm matrix e.g. chelating 
356 agents23 and G-block alginate oligomers31, 74 may be invaluable in the future.   MPT may 
357 further our insight into the potential effects of such antimicrobial therapies in vivo and 
358 provide increased understanding into the biofilm matrix and biofilm-related changes 
359 induced with the acquisition of antibiotic resistance.
360
361 MATERIALS AND METHODS
362 Bacterial strains, growth media and culture conditions.  The following strains 
363 were used in this study; Pseudomonas aeruginosa PAO1, methicillin resistant 
364 Staphylococcus aureus (MRSA 1004A)75, polymyxin B-resistant (PMBR) Escherichia 
365 coli PN47 (carrying the colistin resistance plasmids mcr-1 and mcr-3)76 and polymyxin 
366 B-sensitive (PMBSens) E. coli IR57.  Bacterial colonies were sub-cultured on LB agar 
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367 plates supplemented with/without 2 µg/ml polymyxin B (Sigma-Aldrich).  Overnight 
368 bacterial cultures were grown in Tryptone Soy Broth (TSB; Oxoid) for 37oC at 120 rpm.  
369 Biofilms were grown in cation-adjusted Mueller Hinton Broth (MHB; LabM) 
370 with/without supplementation with the antibiotic polymyxin B. 
371 Minimum Inhibitory Concentration (MIC) measurements.  Overnight bacterial 
372 cultures were adjusted to a standardized cell suspension of approximately 108 colony 
373 forming units (CFU)/ml (equivalent to 0.5 McFarland standard).  Two-fold serial 
374 dilutions in polymyxin B were prepared in MHB within flat bottom 96-well microtiter 
375 plates (100 µl per well).  The adjusted O/N bacterial cultures were then diluted 10-fold in 
376 MHB and 5 µl added to the microtiter plate containing the antibiotic serial dilutions to 
377 give a final concentration of 5 x105 CFU/ml.  The plates were incubated for 16 to 20 h 
378 (37oC) and MICs determined as the lowest concentration at which there was no visible 
379 growth.
380 Biofilm growth.  Overnight bacterial cultures were adjusted to a standardized cell 
381 suspension of 1x107 CFU/ml in MHB.  First, 0.2 ml of adjusted O/N culture was placed 
382 into the center of each glass well within a 12-well dish (glass thickness 1.5 mm and 14 
383 mm diameter; MatTek) and incubated statically for 1 h.  Then, 1.8 ml of fresh MHB was 
384 placed into each well and incubated statically for 24 h at 37oC.  A further 1 ml of MHB 
385 was then placed into each well and plates incubated for a further 24 h (37oC).  Following 
386 48 h growth, biofilms were treated with a further 1 ml of MHB which was added into 
387 each well with a further incubation of 24 h (37oC), resulting in a total biofilm growth 
388 time of 72 h.  
389 Polymyxin B treatment of E. coli biofilms.  Following 48 h growth, E. coli 
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390 biofilms were treated with either 1 ml of MHB (control) or 1 ml polymyxin B (2, 8, 16, 
391 32, 64 µg/ml; treatment) which was added into each well with a further incubation of 24 
392 h (37oC), resulting in a total biofilm growth time of 72 h.  
393 SYTO 9 staining and CLSM imaging of biofilms.  After 72 h growth, the bacterial 
394 supernatant was carefully removed and the bacterial cells within the biofilms stained with 
395 0.5% Syto 9® dye (Invitrogen; 400µl) for 1 h.  After staining, the biofilms were washed 
396 with phosphate buffered saline (PBS; x2) prior either to CLSM Z-stack imaging using a 
397 Leica TCS SP5 CLSM or NP addition.
398 MPT measurement of bacterial biofilms.  NPs used in this study were either 
399 negatively-charged carboxylate-modified Fluospheres® (40, 100, 200 and 500 nm) or 
400 positively-charged amino-modified Fluospheres® (200 nm) ([Ex/Em]: [580/605 nm]; 
401 ThermoFisher Scientific).  The zeta potential and sizing values of the NPs were 
402 characterized in PBS buffer using a Malvern Zetasizer Nano ZS prior to MPT studies.  
403 For MPT experiments, the Fluospheres® suspension was vortexed for 1 min then diluted 
404 in sterilized PBS buffer (0.0025%), before addition of 10 µl diluted Fluospheres®
405 suspension onto the biofilms followed by a 2 h incubation.  Biofilms were stained with 
406 SYTO 9® before addition of the Fluospheres® to visualize the lower layers of the biofilm 
407 matrix using a Leica DM IRB wide-field Epifluorescence microscope (x63 oil immersion 
408 lens).  Videos of particle movement within the biofilms were captured at a frame rate of 
409 33 ms (600 frames, 20 s) using a high speed camera (Allied Vision Technologies, UK) 
410 and then particle trajectories were tracked using ImageJ software (Mosaic) over 2 s to 
411 convert NP movements into metric displacements in both the X and Y directions43, 77.  
412 Ensemble mean square displacement ‹MSD›, effective diffusion coefficient ‹Deff›, and 
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413 heterogeneity of particle diffusion were measured as described in supplementary 
414 materials57; 78.  Here, 120 particle movements were captured in each biofilm well, and 
415 each bacterial strain was tested in triplicate (i.e. 360 particles in total for each biofilm 
416 species). 
417 The viscoelastic properties of the biofilms were assessed by determining the 
418 anomalous diffusion exponent (α).  This was calculated by fitting the power law to 
419 log(‹MSD›) versus log(Δt) and calculating the slope of this data79, where α = 1 for a 
420 completely viscous system (liquid), α = 0 for a completely elastic system (solid) and 1  > 
421 α > 0 for a viscoelastic system39, 40.  Additionally, the micro-rheological properties of the 
422 biofilms were further defined by calculation of the creep compliance (J(Ƭ)), where the 
423 MSD represents deformation of the biofilm within time (Δt) under constant 
424 pressure/shear force represented by the temperature of the atmosphere.  Creep 
425 compliance (J(Ƭ)) was calculated by the following equation: [J(Ƭ)= 3πd/4κT<MSD(Ƭ)]
426 where κ is the Boltzmann constant, T is absolute temperature and d is the diameter of the 
427 particle in µm80. 
428 Statistical analysis.  Statistical software (Minitab, State College, PA) was used to 
429 calculate significant differences with ANOVA testing with post hoc Tukey multi-
430 comparison tests for the statistical analyses presented.
431
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717 Figure 1: Heterogeneity of NP movement through P. aeruginosa PAO1 and S. 
718 aureus 1004A (MRSA) biofilm structures.  Heterogeneity of 40, 100, 200 and 500 nm 
719 –ve charged carboxylate modified FluoSpheres® NPs movement through P. aeruginosa 
720 PAO1 and S. aureus 1004A (MRSA) biofilms.  For each particle type, the effective 
721 diffusion coefficient ‹Deff› was calculated for 360 individual particles (n=3 for biofilm 
722 experiments, each comprised of 120 particles) over a time interval of 20 sec and then data 
723 was ranked into percentiles from the 90th through to 10th percentile. (a and e) -ve 
724 charged 40 nm carboxylate modified FluoSphere ® in P. aeruginosa and S. aureus
725 biofilms respectively; (b and f) -ve charged 100 nm carboxylate modified FluoSphere ® in 
32
726 P. aeruginosa and S. aureus biofilms respectively; (c and g) -ve charged 200 nm 
727 carboxylate modified FluoSphere ® in P. aeruginosa and S. aureus biofilms respectively; 
728 (d and h) -ve charged 500 nm carboxylate modified FluoSphere ® in P. aeruginosa and S. 
729 aureus biofilms respectively. Fold difference in the figure indicates the fold difference 
730 between the 90th and 10th percentiles. 
731
732 Figure 2: Exponential anomalous values ‹α› of P. aeruginosa PAO1 and S. aureus
733 (MRSA) biofilms. Exponential anomalous values ‹α› of (a) P. aeruginosa and (b) S. 
734 aureus biofilms using 40, 100, 200 and 500 nm negatively- charged carboxylate modified 
735 FluoSpheres®. α is measured based on the relation between the ensemble mean square 
736 displacement (MSD) versus time scale of the traced FluoSphere® particles and reflects 
737 the micro-rheological degree of resistance of the biofilm towards traced particles where; 
738 α > 0.5 indicates viscous resistance; α < 0.5 indicates elastic resistance. <MSD> 
739 represents the geometric mean of MSDs of 360 particles (n=3, each 120 particles). 
740
741 Figure 3:  Nanoparticle diffusion within and disruption of E. coli IR57 (PMBSens) 
742 biofilms treated with Polymyxin B. Polymyxin B (PMB)-treated (2, 8, 16, 32, 64 
743 µg/ml) and untreated PMBSens E. coli IR57 biofilms showing: (a) CLSM 3D and side-on 
744 imaging of biofilms grown for 48 h followed by polymyxin B treatment for a further 24 h 
745 at 37oC in MH broth, visualized using Syto9® staining (Scale bar, 40 µm; n=3).  (b) 
746 Diffusion coefficient <Deff> of 100, 200 and 500 nm negatively-charged carboxylate 
33
747 modified FluoSphere® particles in non-treated versus polymyxin B treated biofilms (n=3, 
748 ±SEM). *indicates FluoSphere® particle sizes of 100, 200 and 500 nm. 
749
750 Figure 4: Exponential anomalous values ‹α› of E. coli IR57 (PMBSens) biofilms 
751 treated with Polymyxin B. Exponential anomalous values ‹α› of E. coli IR57 (PMBSens) 
752 biofilms in response to polymyxin B treatment using 100, 200 and 500 nm negatively- 
753 charged carboxylate FluoSpheres® (a) untreated control; (b) 2; (c), 8; (d), 16; (e), 32; and 
754 (f) 64 µg/ml polymyxin B treatment. α is measured based on the relation between the 
755 ensemble mean square displacement (MSD) versus time scale of the traced FluoSphere® 
756 particles and reflects the micro-rheological degree of resistance of the biofilm towards 
757 traced particles where; α > 0.5 indicates viscous resistance; α < 0.5 indicates elastic 
758 resistance. <MSD> represents the geometric mean of MSDs of 360 particles (n=3, each 
759 120 particles). 
760
761 Figure 5: Creep Compliance of E. coli IR57 biofilms treated with Polymyxin B.
762 Creep compliance (J(Ƭ)) of E. coli IR57 (PMBSens) biofilms (measured using the 
763 ensemble mean square displacement <MSD> versus lag time of 100, 200 and 500 nm 
764 negatively-charged carboxylate modified FluoSphere® particles) representing biofilm 
765 deformation in response to polymyxin B treatment (2, 8, 16, 32 and 64 µg/ml) versus 
766 untreated biofilm. (a) Untreated E.coli biofilms for 100, 200 and 500 nm FluoSphere® 
767 particles and (b) 100 nm FluoSphere® particles, (c) 200 nm FluoSphere® particles (d) 
768 500 nm FluoSphere® particles, in response to polymyxin B treatment. 
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769
770 Figure 6: Heterogeneity of NP movement through PMBSens E. coli IR57 and PMBR
771 E. coli PN47 biofilm structures +/- Polymyxin B treatment. Heterogeneity of 200 nm 
772 negatively-charged carboxylate modified FluoSpheres® movement within E. coli
773 biofilms. Untreated controls (a) PMBSens E. coli IR57, (b) PMBR E. coli PN47.  
774 Polymyxin B- (PMB; 8 µg/ml) treated biofilms (c) PMBsens E. coli IR57, (d) PMBR E. 
775 coli PN47.  For each particle type, the effective diffusion coefficient ‹Deff› was 
776 calculated for 360 individual particles (n=3 for biofilm experiments, each comprised of 
777 120 particles) over a time interval of 20 sec and the data ranked into percentiles (90th to 
778 10th). Fold difference in the figure indicates the fold difference between the 90th and 10th 
779 percentiles.
780
781 Figure 7: Creep compliance of PMBSens E. coli IR57 and PMBR E. coli PN47 biofilm 
782 structures +/- Polymyxin B treatment. Creep compliance (J(Ƭ)) of polymyxin B- 
783 (PMB, 8 µg/ml) treated (dashed lines) and untreated control (solid lines) E. coli IR57 and
784 PN47 biofilms (measured using ensemble mean square displacement <MSD> versus time 
785 of 200 nm negatively-charged carboxylate modified FluoSphere® particles) .
786
787 Supplementary Figure 1: Comparison of P. aeruginosa and S. aureus biofilm 
788 structures. CLSM 3D imaging of (a) P. aeruginosa PAO1 and (b) S. aureus 1004A 
789 (MRSA) biofilms grown for 72 h at 37oC in MH broth, using Syto9® staining (Scale bar, 
790 40 µm; n=3).
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TABLE 1. NP diffusion within P. aeruginosa PAO1 and MRSA biofilm structures. Diffusion coefficients of 40, 100, 200 and 500 nm 
negatively charged carboxylate modified FluoSpheres® and positively-charged amine modified FluoSpheres® in water calculated by Stoke-
Einstein equation versus their effective diffusion coefficients through P. aeruginosa PAO1 and S. aureus (MRSA) biofilms measured by the 
MPT technique. 
Diffusion properties Physicochemical properties of FluoSphere®
particles
P. aeruginosa biofilms S. aureus biofilms
FluoSphere® Particle size 
(nm)      
Mean (PDI)
Zeta potential 























carboxylate 54.73 (0.08) -37.86 (±0.85) 82.11 3.1493 (±0.6071) 3.8352 1.1584 (±0.1945) 1.4107
-ve 
carboxylate 108.9 (0.026) -40.96 (±2.05) 41.27 1.6647 (±0.3695) 4.0338 0.3549 (±0.0624) 0.8600
-ve 
carboxylate 239.4 (0.031) -40.83 (±1.30) 18.77 0.0358 (±0.0067) 0.1907 0.0031 (±0.0006) 0.0165
-ve 
carboxylate 517.2 (0.059) -40.83 (±2.07) 8.69 0.0165 (±0.0038) 0.1899 0.0038 (±0.0007) 0.0437
+ve amine 204.2 (0.029) +8.90 (±0.53) 22.01 0.0061 (±0.0015) 0.0277 0.0074 (±0.0017) 0.0336
<Deff>PAO1 and <Deff>MRSA indicate <Deff> in PAO1 and MRSA biofilms respectively.   (n=3, ±Standard Error of the Mean SEM).  PDI  
Polydispersity Index.
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TABLE 2. NP diffusion within PMBR and PMBsens E. coli biofilms +/- polymyxin B treatment. Diffusion coefficients <Deff> of 
200 nm negatively charged carboxylate modified FluoSpheres® in water (calculated by Stoke-Einstein equation) versus their effective 
diffusion coefficients (measured by MPT) through PMBR and PMBsens E. coli biofilms with/without polymyxin B treatment (8 µg/ml).
E. coli strain
Polymyxin B 
treatment              
(8 µg ml-1)
Diffusion coefficient 
in water (D°)      
(cm2/s x 10-9)
Diffusion coefficient 
<Deff> E. coli (cm




- 22.47 0.0643 (±0.0158) 0.2863PMBsens IR57
+ 22.47 0.3400 (±0.0805) 1.5121
- 22.47 0.0198 (±0.0038) 0.0880PMBR PN47 + 22.47 0.0137 (±0.0025) 0.0610
<Deff>E. coli indicates <Deff> in PMB
R and PMBsens E. coli biofilms (n=3, ±Standard Error of the Mean SEM). 
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FIG 1 Heterogeneity of NP movement through P. aeruginosa PAO1 and S. aureus 1004A (MRSA) biofilm structures.  Heterogeneity of 40, 100, 200 and 
500 nm –ve charged carboxylate modified FluoSpheres® NPs movement through P. aeruginosa and  S. aureus biofilms.  For each particle type, the effective 
diffusion coefficient ‹Deff› was calculated for 360 individual particles (n=3 for biofilm experiments, each comprised of 120 particles) over a time interval of 20 
sec and then data was ranked into percentiles from the 90th through to 10th percentile. (a and e) -ve charged 40 nm carboxylate modified FluoSphere ® in P. 
aeruginosa and S. aureus biofilms respectively; (b and f) -ve charged 100 nm carboxylate modified FluoSphere ® in P. aeruginosa  and S. aureus biofilms 
respectively; (c and g) -ve charged 200 nm carboxylate modified FluoSphere ® in P. aeruginosa and S. aureus  biofilms respectively; (d and h) -ve charged 500 
nm carboxylate modified FluoSphere ® in P. aeruginosa and S. aureus  biofilms respectively. Fold difference in the figure indicates the fold difference between 
the 90th and 10th percentiles. 
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FIG 2 Exponential anomalous values ‹α› of P. aeruginosa PAO1 and S. aureus 1004A (MRSA) biofilms. Exponential anomalous values ‹α› of (a) P. 
aeruginosa and (b) S. aureus biofilms using 40, 100, 200 and 500 nm negatively- charged carboxylate modified FluoSpheres®. α is measured based on the 
relation between the ensemble mean square displacement (MSD) versus time scale of the traced FluoSphere® particles and reflects the micro-rheological 
degree of resistance of the biofilm towards traced particles where; α > 0.5 indicates viscous resistance; α < 0.5 indicates elastic resistance. <MSD> represents 
the geometric mean of MSDs of 360 particles (n=3, each 120 particles). 









Control 2 µg/ml 8 µg/ml
16 µg/ml 32 µg/ml 64 µg/ml
FIG 3  Nanoparticle diffusion within and disruption of E. coli IR57 (PMBSens) biofilms treated with polymyxin B. Polymyxin B (PMB)-treated (2, 8, 16, 
32, 64 µg/ml) and untreated PMBSens E. coli IR57 biofilms showing: (a) CLSM 3D and side-on imaging of biofilms grown for 48 h at 37oC in MH broth 
followed by polymyxin B treatment for a further 24 h in MH broth, visualized using Syto9® staining (Scale bar, 40 µm; n=3).  (b) Diffusion coefficient <Deff> 
of 100, 200 and 500 nm negatively-charged carboxylate modified FluoSphere® particles in non-treated versus polymyxin B treated biofilms (n=3, SEM). 
*indicates FluoSphere® particle sizes of 100, 200 and 500 nm. 
a                                                                                                            b
*
**
 a                                            b                                            c   
d                                            e                                            f   
Untreated 2 µg/ml 8 µg/ml
16 µg/ml 32 µg/ml 64 µg/ml
FIG 4 Exponential anomalous values ‹α› of E. coli IR57 (PMBSens) biofilms treated with polymyxin B. Exponential anomalous values (α) of E. coli biofilms in 
response to polymyxin B treatment using 100, 200 and 500 nm negatively- charged carboxylate FluoSpheres® (a) untreated control; (b) 2; (c), 8; (d), 16; (e), 32; and 
(f) 64 µg/ml polymyxin B treatment. α is measured based on the relation between the ensemble mean square displacement (MSD) versus time scale of the traced 
FluoSphere® particles and reflects the micro-rheological degree of resistance of the biofilm towards traced particles where; α > 0.5 indicates viscous resistance; α < 0.5 
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FIG 5 Creep Compliance of E. coli IR57 
(PMBSens) biofilms treated with Polymyxin B. 
Creep compliance (J(Ƭ)) of E. coli biofilms 
(measured using the ensemble mean square 
displacement <MSD> versus lag time of 100, 200 
and 500 nm negatively-charged carboxylate 
modified FluoSphere® particles) representing 
biofilm deformation in response to polymyxin B 
treatment (2, 8, 16, 32 and 64 µg/ml) versus 
untreated biofilm. (a) Untreated E .coli biofilms 
for 100, 200 and 500 nm FluoSphere® particles 
and (b) 100 nm FluoSphere® particles, (c) 200 
nm FluoSphere® particles (d) 500 nm 
FluoSphere® particles, in response to polymyxin 
B treatment. 
a                                            b
c                                            d
Untreated 100 nm
500 nm200 nm
FIG 6 Heterogeneity of NP movement through PMBSens E. coli IR57 and PMBR E. coli PN47 biofilm structures +/- Polymyxin B treatment. Heterogeneity of 
200 nm negatively-charged carboxylate modified FluoSpheres® movement within E. coli biofilms. Untreated controls (a) PMBSens E. coli IR57, (b) PMBR E. coli 
PN47.  Polymyxin B- (PMB; 8 µg/ml) treated biofilms (c) PMBsens E. coli IR57, (d) PMBR E. coli PN47.  For each particle type, the effective diffusion coefficient 
‹Deff› was calculated for 360 individual particles (n=3 for biofilm experiments, each comprised of 120 particles) over a time interval of 20 sec and the data ranked 
into percentiles (90th to 10th). Fold difference in the figure indicates the fold difference between the 90th and 10th percentiles.
a                                                       b
c                                                      d










FIG 7 Creep compliance of PMBSens E. coli IR57 and PMBR E. coli PN47 biofilm structures +/- Polymyxin B treatment. Creep compliance (J(Ƭ)) of 
polymyxin B- (PMB, 8 µg/ml) treated (dashed lines) and untreated control (solid lines) E. coli IR57 and PN47 biofilms (measured using ensemble mean 
square displacement <MSD> versus time of 200 nm negatively-charged carboxylate modified FluoSphere® particles) .
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P. aeruginosa bacterial strain
P. aeruginosa PAO1 used in this study closely resembles PAO1_Orsay and PAO1_ ATCC 
15692 strains, as demonstrated in high-throughput genome resequencing in an unrelated 
study (European Nucleotide Archive[ENA] project number PRJEB36146 and accession 
number for the draft genome sequence GCA_902860215).
Calculation of mean square displacement ‹MSD›, effective diffusion coefficient ‹Deff›, 
and heterogeneity of particle diffusion
The mean square displacement ‹MSD› was determined as follows:
() = (∆)2 + (∆)2
where the distance the nanoparticle (n) moved over a selected time frame (t) in the X-Y 
trajectory was expressed as a squared displacement (SD).
The effective diffusion coefficient ‹Deff›, of the nanoparticles determined by the following 
equation:
〈〉= 〈〉/(4 ∗ ∆)
where 4 is a constant relating to the 2-dimensional mode of video capture and Δt is the 
selected time interval. 
Nanoparticle diffusion in water (D°) was calculated by the Stokes–Einstein equation at 37 oC:
° = /6
where к is Boltzmann constant, T is absolute temperature, η is water viscosity, and r is radius 
of the nanoparticle. The diffusion of the nanoparticles was also expressed as the parameter, % 
ratio [Deff]/[D°]. The heterogeneity of particle diffusion was measured by profiling the 
diffusion coefficients (Δt= 2 sec) of all individual particles within the entire population (360 
particles) from the highest (90th) to the lowest (10th) percentiles in ‹Deff› values. 
Error arising from experimental noise
The error arising from experimental noise (tracking resolution [σ]) was measured for each of 
the FluoSphere particles individually, by fixing (cyanoacrylate-based glue) the particles onto 
a glass-bottomed imaging dish (MatTek life sciences) and tracking their movements.  Using 
this set-up, 20 videos were analysed using ImageJ software with Mosaic plugin to 
independently measure σ2 by determining the X- and Y-directional displacement of the 
particles at the lowest temporal resolution (0.033 frame per second). The value of σ2 was 
subtracted from the MSD measurement at the lowest frame rate to achieve final measurements 
of MSD and <Deff>. The calculated values of σ ranged between 3.45 to 3.96 nm for each of 
the Fluospheres (Supplementary Table 1). 
SUPPLEMENTARY TABLE 1. Tracking resolution of the FluoSphere® particles
FluoSpheres® Particle size (nm) σ (nm) 
-ve carboxylate 40 3.96
-ve carboxylate 100 3.82
-ve carboxylate 200 3.45
-ve carboxylate 500 3.56
+ve amine 200 3.69
S. aureus 1004A (MRSA) P. aeruginosa PAO1 
SUPPLEMENTARY FIG 1 Comparison of P. aeruginosa and S. aureus biofilm structures.  CLSM 3D 
imaging of (a) P. aeruginosa PAO1 and (b) S. aureus 1004A (MRSA) biofilms grown for 72 h at 37oC in MH 
broth, using Syto9® staining (Scale bar, 40 µm; n=3).
a                                     b                                      
